Thérèse Aurran

639 total citations
19 papers, 257 citations indexed

About

Thérèse Aurran is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Thérèse Aurran has authored 19 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in Thérèse Aurran's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (12 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Thérèse Aurran is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (12 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Thérèse Aurran collaborates with scholars based in France, Belgium and Australia. Thérèse Aurran's co-authors include Stéphane Leprêtre, Véronique Leblond, Youn K. Shim, Sylvie Chevret, Neil E. Caporaso, Gerald E. Marti, Fatima Abbasi, Paolo Ghia, Elizabeth Raveché and Robert F. Vogt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Thérèse Aurran

18 papers receiving 252 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thérèse Aurran France	8	202	178	80	45	40	19	257
Andrew Aw Canada	9	144 0.7×	106 0.6×	54 0.7×	38 0.8×	40 1.0×	21	272
Giorgia Annechini Italy	10	73 0.4×	147 0.8×	45 0.6×	132 2.9×	30 0.8×	25	287
Polina Kaplan Poland	6	283 1.4×	228 1.3×	94 1.2×	59 1.3×	116 2.9×	9	331
Richard F Schlenk Germany	5	312 1.5×	252 1.4×	159 2.0×	56 1.2×	62 1.6×	5	368
Shenmiao Yang China	7	177 0.9×	150 0.8×	83 1.0×	63 1.4×	92 2.3×	37	296
Zdravko Mitrović Croatia	10	95 0.5×	160 0.9×	51 0.6×	117 2.6×	32 0.8×	30	255
Michaela Rancea Germany	5	73 0.4×	236 1.3×	24 0.3×	144 3.2×	27 0.7×	11	301
Joi Ninomoto United States	11	376 1.9×	300 1.7×	118 1.5×	46 1.0×	148 3.7×	19	407
M. Maynadié France	6	118 0.6×	131 0.7×	37 0.5×	60 1.3×	47 1.2×	6	236
Talha Munir United Kingdom	5	331 1.6×	264 1.5×	135 1.7×	42 0.9×	97 2.4×	16	365

Countries citing papers authored by Thérèse Aurran

Since Specialization

Citations

This map shows the geographic impact of Thérèse Aurran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thérèse Aurran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thérèse Aurran more than expected).

Fields of papers citing papers by Thérèse Aurran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thérèse Aurran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thérèse Aurran. The network helps show where Thérèse Aurran may publish in the future.

Co-authorship network of co-authors of Thérèse Aurran

This figure shows the co-authorship network connecting the top 25 collaborators of Thérèse Aurran. A scholar is included among the top collaborators of Thérèse Aurran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thérèse Aurran. Thérèse Aurran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Roos‐Weil, Damien, Cécile Tomowiak, Stéphanie Poulain, et al.. (2025). Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines. European Journal of Cancer. 232. 116120–116120.

Tomowiak, Cécile, Stéphanie Poulain, Pierre Feugier, et al.. (2024). Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia. Annals of Hematology. 104(1). 685–690. 2 indexed citations

Tomowiak, Cécile, Stéphanie Poulain, Charles Herbaux, et al.. (2021). Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Advances. 5(9). 2438–2446. 21 indexed citations

Cautela, Jennifer, Noémie Resseguier, Thérèse Aurran, et al.. (2019). High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 6(1). e001049–e001049. 48 indexed citations

Leblond, Véronique, Pierre Morel, Xavier Leleu, et al.. (2017). A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. Leukemia & lymphoma. 58(11). 2615–2623. 7 indexed citations

Apostolidis, Thémis, et al.. (2016). Patients’ Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings. PLoS ONE. 11(5). e0154969–e0154969. 20 indexed citations

Gottlieb, David, Thérèse Aurran, Constantine S. Tam, et al.. (2016). Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Blood. 128(22). 2053–2053. 2 indexed citations

Dartigeas, Caroline, Eric Van Den Neste, Hervé Maisonneuve, et al.. (2016). Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (≥ 65 years) CLL patients: Results of the randomized CLL 2007 SA trial from the French FILO Group (NCT00645606).. Journal of Clinical Oncology. 34(15_suppl). 7505–7505. 5 indexed citations

Meunier, Godelieve, Loïc Ysebaert, Phi‐Linh Nguyen‐Thi, et al.. (2016). First‐line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. Hematological Oncology. 35(4). 671–678. 4 indexed citations

10.

Leprêtre, Stéphane, Caroline Dartigeas, Hervé Maisonneuve, et al.. (2014). Results of a Phase II Randomizing Intensified Rituximab Pre-Phase Followed By Standard FCR Vs Standard FCR in Previously Untreated Patients with Active B-Chronic Lymphocytic Leukemia (B-CLL). CLL2010FMP (for fit medically patients): A Study of the french Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS). Blood. 124(21). 3329–3329. 2 indexed citations

11.

Leblond, Véronique, Sylvie Chevret, Xavier Leleu, et al.. (2013). Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738). Blood. 122(21). 4359–4359. 2 indexed citations

12.

Leprêtre, Stéphane, Thérèse Aurran, Beatrice Mahé, et al.. (2012). Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 119(22). 5104–5110. 66 indexed citations

13.

Cazin, Bruno, Stéphane Leprêtre, Bertrand Coiffier, et al.. (2011). Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood. 118(21). 2862–2862. 7 indexed citations

14.

Rey, Jérôme, Rémy Castellano, Florence Orlanducci, et al.. (2011). Defective Triggering of NK Cells Results in Primary CLL Cells Resistance to Cytotoxicity,. Blood. 118(21). 3876–3876. 1 indexed citations

15.

Cartron, Guillaume, Bruno Cazin, Bertrand Coiffier, et al.. (2010). A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood. 116(21). 2447–2447. 2 indexed citations

16.

Leprêtre, Stéphane, Thérèse Aurran, Bruno Cazin, et al.. (2009). Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang” (GOELAMS) : CLL2007FMP (for fit medically patients).. Blood. 114(22). 538–538. 7 indexed citations

17.

Marti, Gerald E., Fatima Abbasi, Elizabeth Raveché, et al.. (2007). Overview of monoclonal B‐cell lymphocytosis. British Journal of Haematology. 139(5). 701–708. 50 indexed citations

18.

Cheikh, Jean El, Christian Chabannon, Anne‐Marie Stoppa, et al.. (2007). Autologous Stem Cell Transplantation (auto-SCT) in Elderly Patients with Multiple Myeloma (MM): Age per se Does Not Affect Outcome.. Blood. 110(11). 947–947. 1 indexed citations

19.

Coso, Diane, Catherine Sebban, Olivier Boulat, et al.. (2006). A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Bone Marrow Transplantation. 38(3). 217–222. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact